8/19/2014 - 3:44 PM EST - Bioniche Life Sciences Inc. : announced that it is targeting Q1/2015 for the filing of a Biologics License Application with the United States Food and Drug Administration for Bioniche's lead program Mycobacterial Cell Wall-Nucleic Acid Complex for the treatment of patients with high grade non-muscle invasive bladder cancer that have failed Bacillus Calmette-Guérin therapy. Bioniche Life Sciences Inc.
shares T.BNC are trading up $0.015 at $0.29.
